213763-99-6

Basic information

• Product Name: 2-Benzyl-4-isopropoxy-5-[4-(methylsulfonyl)phenyl]pyridazin-3(2H)-one
• Synonyms: L-804600
• CAS NO: 213763-99-6
• Molecular Formula: C₂₁H₂₂N₂O₄S
• Molecular Weight: 398.48449
• Mol File: 213763-99-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-Benzyl-4-isopropoxy-5-[4-(methylsulfonyl)phenyl]pyridazin-3(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Benzyl-4-isopropoxy-5-[4-(methylsulfonyl)phenyl]pyridazin-3(2H)-one(213763-99-6)
• EPA Substance Registry System: 2-Benzyl-4-isopropoxy-5-[4-(methylsulfonyl)phenyl]pyridazin-3(2H)-one(213763-99-6)

Safety Data

• Hazardous Substances Data: 213763-99-6(Hazardous Substances Data)

Upstream product

• 7732-18-5 water 
• 213764-20-6 2-benzyl-4-bromo-5-(4-methylsulfonyl)phenyl-2H-pyridazin-3-one 
• 552865-15-3 4-bromo-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one 
• 552865-14-2 3-bromo-5-hydroxy-4-(4-methanesulfonyl-phenyl)-5H-furan-2-one 
• 552865-13-1 3-bromo-4-(4-methanesulfonyl-phenyl)-5H-furan-2-one 
• 162012-28-4 4-(4-(methylthio)phenyl)furan-2(5H)-one 
• 98546-51-1 (4-thiomethoxyphenyl)boronic acid 
• 67-63-0 isopropyl alcohol 

Downstream Products

• 213764-00-2 2-benzyl-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone 

Relevant articles and documents

PYRIDAZINONES AS INHIBITORS OF CYCLOOXYGENASE-2

The invention encompasses the pyridazin-3-one compounds of formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a

Prostaglandin endoperoxide H synthase biosynthesis inhibitors

The present invention describes pyridazinone compounds of formula I which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).